Shares of GlaxoSmithKline (NYSE:GSK) have been given an average rating of “Hold” by the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $40.00.
GSK has been the topic of several analyst reports. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Deutsche Bank reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Wednesday, March 28th. BNP Paribas upgraded shares of GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, February 2nd.
Several hedge funds have recently made changes to their positions in GSK. We Are One Seven LLC raised its holdings in GlaxoSmithKline by 185.1% in the first quarter. We Are One Seven LLC now owns 2,677 shares of the pharmaceutical company’s stock valued at $105,000 after buying an additional 1,738 shares during the period. Adviser Investments LLC purchased a new position in GlaxoSmithKline in the first quarter valued at approximately $117,000. Toronto Dominion Bank raised its holdings in GlaxoSmithKline by 133.3% in the first quarter. Toronto Dominion Bank now owns 3,150 shares of the pharmaceutical company’s stock valued at $123,000 after buying an additional 1,800 shares during the period. Field & Main Bank purchased a new position in GlaxoSmithKline in the fourth quarter valued at approximately $132,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in GlaxoSmithKline in the first quarter valued at approximately $135,000. Institutional investors and hedge funds own 11.12% of the company’s stock.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.70 by ($0.02). GlaxoSmithKline had a return on equity of 144.84% and a net margin of 3.50%. The firm had revenue of $10.04 billion for the quarter, compared to analyst estimates of $10.26 billion. analysts forecast that GlaxoSmithKline will post 2.95 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 12th. Stockholders of record on Friday, May 11th will be issued a dividend of $0.5298 per share. The ex-dividend date is Thursday, May 10th. This represents a $2.12 annualized dividend and a dividend yield of 5.28%. GlaxoSmithKline’s payout ratio is currently 72.92%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.